Based on these observations, three classes of mTOR inhibitors are included in the scenario of ALL treatment: allosteric inhibitors [(rapamycin and rapalogs, that are, RAD001 (everolimus), CCI-779 (temsirolimus)] mainly targeting mTORC1 [80,81,82], ATP-competitive dual PI3K/mTOR inhibitors [6,83,84] and mTOR kinase inhibitors (TORKIs) that specifically have as a target mTORC1 and mTORC2 but not PI3K [79,83,85]. Here, MTOR is linked to acute lymphoblastic leukemia.